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Case Report
Sustained Remission in a Case of Lupus Nephritis
with Cyclosporin Therapy
Malik Anas Rabbani, Syed Mansoor Ahmad Shah, Aasim Ahmad
Department of Medicine, Aga Khan University Hospital,
Stadium Road, Karachi, Pakistan
ABSTRACT. Systemic lupus erythematosus (SLE) in severe form still presents a major
therapeutic challenge. Aggressive treatment of severe renal lesions has improved the
prognosis of renal disease over the last decade. However, this benefit is quite frequently
offset by the side effects and toxicity of the treatment. Moreover, the disease may appear to
be poorly responsive to treatment with steroids and cytotoxic drugs. We report a case of
lupus nephritis that relapsed despite having adequate steroid and cytotoxic therapy, but later
was successfully treated with cyclosporin. Fifteen months after discontinuing the treatment
with cyclosporin, the patient continued to remain in remission.
Key words: Systemic lupus erythematosus, Lupus nephritis, Cyclosporin A.
Introduction
Systemic lupus erythematosus (SLE) in
severe form still presents a major therapeutic
challenge. Renal involvement in SLE is
variable; some patients have minimal
clinical and histological involvement, while
others have fulminant renal failure and
severe proliferative renal lesions on biopsy.1
Reprint requests and correspondence to:
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Aga Khan University Hospital
Stadium Road, P.O. Box 3500,
Karachi-74800, Pakistan

The World Health Organization (WHO)
classification,2 which defines six major
patterns of renal involvement, has greatly
helped to study lupus nephritis. Transformation from one pattern of lupus
nephritis to another may occur.3 The
optimal treatment of lupus nephritis varies
with the type of disease. Aggressive
immunosuppression is required for the
more severe renal lesions such as diffuse or
more severe focal proliferative glomerulonephritis (GN) and severe and progressive
membranous GN (WHO Classes III, IV and
V) as these lesions are at high risk for
progressing to renal failure.4 Aggressive
treatment of the severe renal lesions has

[Downloaded free from http://www.sjkdt.org on Wednesday, October 17, 2018, IP: 221.132.113.70]

526

improved the prognosis of renal disease
over the last decade. However, this benefit
is quite frequently offset by the side effects
and toxicity related to drugs.5 Moreover,
disease may itself be poorly responsive to
treatment with steroids and cytotoxic drugs.
Cyclosporin A (CSA) is used as a corner
stone in the prevention of graft rejection inpatients who receive organ transplants. It
has also been used in various autoimmune
disorders including systemic lupus erythematosus (SLE) because of its selective
immunosuppressive effect.
We report here a case of lupus nephritis,
which had frequently relapsed despite high
dose steroids and cyclophosphamide and
later was successfully managed with CSA
based therapy.
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Case Report
A sixteen year old boy was admitted at the
Aga Khan University Hospital with a one
week history of high grade fever associated
with chills and rigors, arthralgias involving
hands, feet, knee and ankle joints and
generalized purpuric rash. On examination,
the pulse was 110/min, blood pressure 140/90
mm Hg, respiratory rate 27/min and temperature 39°C. Chest examination revealed
bilateral pleural effusions. Abdominal
examination revealed hepatosplenomegaly
without ascites. Mild pedal edema was
noted.
Laboratory investigations revealed hemoglobin of 102 gm/L, WBC 1.6 × 109/L,
platelets 2.8 × 109/L, ESR 61 mm/hour.

Figure 1. The renal biopsy showing large hypercellular glomerulus with lobular capillary tufts. The
capillary lumina are obliterated by endocapillary cell proliferation and leukocytic infiltration. The tubules
show vacuolar changes and the interstitium is slightly edematous (H & E Stain, Magnification x 200).
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Serum creatinine and electrolytes were
within normal range. Serum C3 was 0.123u
(N-0.5-0.9), serum C4 < 0.05u, anti (ds)
DNA 2451 IU (Range 0-6 IU) and ANA
strongly +ve. Liver function tests, prothrombin time and activated thrompoplastin
time were normal. Chest x-ray confirmed
the presence of bilateral pleural effusions.
Urinalysis revealed +3 protein and microscopic hematuria. 24-hour urine specimen
revealed creatinine clearance of 98 ml/min
and proteinuria of 3.6 gm/day. Renal biopsy
was consistent with WHO class IV histological pattern, Figure 1. Immunoflourescence of the renal biopsy revealed
immunoglobulin deposits of IgG, IgM, IgA,
C3 and C4.
The patient was treated with pulse
methylprednisolone one gram/day for three
days followed by oral steroids (1 mg/kg of
body weight) and Azathioprine (1.5 mg/kg
of body weight). The blood counts returned
to normal values within a week and the
proteinuria decreased from 3.6 gm/day to
158 mg/day over the following three months.
In the next six months the proteinuria
relapsed twice despite the oral steroids and
azathioprine. Each episode was treated with
pulse methylprednisolone to which the patient
responded well with protein excretion
decreasing to less than 500 mg/day.
Subsequently, the patient had a third relapse
with proteinuria of 5 grams/day. At this
point, oral cyclophosphamide (1.5 mg/kg of
body weight) was substituted for azathioprine. This resulted in marked improvement
as the protinuria disappeared. In order to
avoid the risk of gonadal toxicity, cyclophosphamide was withdrawn after 12 weeks
and the patient was maintained on oral
steroids and azathioprine. Unfortunately,
proteinuria relapsed within three months
after discontinuing the cyclophosphamide.
Cyclosporin was then added along with
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steroids, which resulted in gradual improvement over the following three months and
the proteinuria decreased to less than 100
mg/day. During the first three month of
CSA therapy, the drug was given in a dose
of 3 mg/kg of body weight and the whole
blood CSA level was maintained between
120-180 ng (radioimmune assay (RIA) with
monoclonal antibodies). Cyclosporin was
continued for further six months in a dose
of 1.5-2 mg/kg of body weight and during
this period the whole blood CSA level was
maintained between 120-150 ng (RIA with
monoclonal antibodies). CSA was withdrawn
gradually over the following few weeks.
Fifteen months after withdrawal of all the
treatment the patient continued to be
proteinuria free with creatinine clearance of
124 ml/min.
Discussion
Lupus nephritis is a very complex autoimmune renal disease. Successful treatment
remains challenging due to lack of understanding of the underlying mechanisms and
multiple symptoms ranging from skin
rashes to glomerulonephritis. B cell hyperproliferation is characteristic of active SLE,
which results in raised levels of circulating
immunoglobulins and wide spread deposition
of immune complexes in various tissues.6
Several inflammatory and cell growth
modifying processes also contribute to
tissue destruction.
Lupus nephritis may run an extremely
variable course and though specific therapy
is not required in mild cases, a careful
surveillance is required to detect possible
transformation to a more severe disease
state and flare ups.3 Vigorous treatment
should be started early in patients with
more severe forms of lupus nephritis that
show active lesion in the renal biopsy such
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as glomerular cell proliferation, necrosis,
crescent formation, significant subendothelial
immune complex deposition and inflammation.7 Therapeutic modalities currently
employed in lupus nephritis include oral
corticosteroids, high dose pulse steroid
therapy, cytotoxic drugs like cyclophosphamide and azathioprine, used either
singly or in combination with steroids.
Other therapeutic approaches such as
mycophenolate mofetil and Tacrolimus
have been used in the treatment of severe
and difficult cases of SLE and have been
shown to prolong life span, reduce
proteinuria and prevent progression to
nephropathy.8,9 Intravenous immunoglobulins
and monoclonal antibodies have also been
used in experiments, but their efficacy was
modest.10,11 Plasma exchange therapy has
been used for bulk depletion of immunoreactants. However, multicentre studies
have confirmed no additional role of plasma
exchange therapy in combination with
cytotoxics when compared with sole shortterm use of cytotoxics in terms of patient
survival, frequency of renal failure and
other complications.12 Total lymphoid
radiation has been claimed to be effective in
some cases of refractory lupus nephritis, a
practical perspective on this form of
immunosuppressive therapy has yet to be
developed.13
Cyclosporin A (CSA) is a highly lipophilic cyclic peptide with 11 amino-acids. It
blocks IL-2 synthesis by preventing
transcription of IL-2 gene. Key steps are
binding of CSA to a specific immunophillin, blocking calcineurin and preventing
the transcription of the gene of IL-2.14
Studies have shown that CSA is effective
in reducing the activity of SLE and in
controlling changes in clinical and
laboratory parameters associated with
disease especially in patients with poor
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response to conventional regimens.15 The
overall clinical benefit is usually observed
within 2-4 months of CSA therapy.
Therefore, prolonged treatment should be
aimed at consolidating rather than
achieving further improvement.16 A large
single center, prospective randomized study
published from Italy evaluated disease
activity according to systemic lupus activity
measure (SLAM Score) in 27 patients who
completed at least 24 months of treatment
with CSA. It confirmed that the mean
disease activity score could significantly be
reduced in terms of stabilizing renal
function,
reducing
proteinuria,
and
normalizing leukopenia and thrombocytopenia after six months of CSA therapy.
This result was maintained through out the
study.16
However, the use of CSA is limited
mainly by its tendency to induce hypertension and nephrotoxicity as well as the
tendency to relapse after discontinuing the
treatment.16 Despite this, we believe that the
use of CSA still needs to be further
evaluated as an alternative to cyclophosphamide in the management of lupus in
young patients, especially in pregnant
females in view of its established safety
concerning teratogenicity,17 or as a second
line agent for patient whose condition is
poorly responsive or less tolerant to more
conventional therapy. Prognosis and overall
success certainly varies widely among
geographically and racially diverse
populations.18
We reported a case of lupus nephritis that
relapsed despite having adequate steroid
and cytotoxic therapy, but later was
successfully treated with cyclosporin.
Fifteen months after discontinuing the
treatment with cyclosporin, the patient
continued to remain in remission.
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